Skip to main content

Table 3 Diagnostic performance of the 25-Gene Panel urine test in a retrospective training cohort (n = 614), a prospective validation cohort (n = 396), a combination cohort (n = 1010), and cross-validation of the combination cohort (n = 1010)

From: Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up

 

Retrospective cohort

Prospective cohort

Combination cohort

Cross-validation

 

Positive

Negative

Total

Positive

Negative

Total

Positive

Negative

Total

Positive

Negative

Total

PCa

481

39

520

176

31

207

657

70

727

644

83

727

Non-PCa

8

86

94

10

179

189

18

265

283

27

256

283

Total

489

125

614

186

210

396

675

335

1010

671

339

1010

Sensitivity (95% CI)

92.5% (94.8–90.2%)

85.0% (89.9–80.2%)

90.4% (92.5–88.2%)

88.6% (90.9–86.3%)

Specificity (95% CI)

91.5% (97.1–85.9%)

94.7% (97.9–91.5%)

93.6% (96.5–90.8%)

90.5% (93.9–87.0%)

PPV (95% CI)

98.4% (99.5–97.2%)

94.6% (97.9–91.4%)

97.3% (98.6–96.1%)

96.0% (97.5–94.5%)

NPV (95% CI)

68.8% (76.9–60.7%)

85.2% (90.0–80.4%)

79.1% (83.5–74.8%)

75.5% (80.1–70.9%)

Odds ratio (95% CI)

132.6 (293.5–59.9)

101.6 (213.5–48.4)

138.2 (236.5–80.8)

73.6 (116.3–46.6)

  1. PPV positive predictive value, NPV negative predictive value, CI confidence interval